arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences,

FT Global Pharmaceutical and Biotechnology Conference 2015

Bringing Innovation to Patients: New Approaches, Models, Challenges

London |  - 
Speakers include:
Severin Schwan

Severin Schwan

Roche Group

SeungSuh (Stanley) Hong

SeungSuh (Stanley) Hong

Celltrion Healthcare

Jim O'Neill

Jim O'Neill

The Review of Antimicrobial Resistance

Overview

As the global healthcare industry shifts and transforms, so too must the life science industry.  Life science companies will need to adjust strategies to a world in which only true innovation and improved patient outcomes become the key determinant of value in the healthcare system. They will also need to develop commercial models which take account of the changing power balance between provider, payer and patients-all the while keeping a watchful eye on the competitive landscape for the incursion of non-traditional players with whom they will increasingly compete-or partner- to deliver patient-centred products and services. Meanwhile, scrutiny of high prices for speciality drugs and advanced technologies is increasing, impacting the ability of life science companies to bring much needed innovation to patients.

How will the industry’s future unfold?

The FT Global Pharmaceutical and Biotechnology Conference, now in its 33rd successful year, is a must-attend for industry executives, thought leaders and investors wishing to keep abreast of the emerging trends reshaping the global healthcare and life sciences industry.

Download the Event Brochure here >>

fallback
fallback Add to my Calendar 11/16/2015 09:00:0011/17/2015 12:55:00trueFT Global Pharmaceutical and Biotechnology Conference 2015As the global healthcare industry shifts and transforms, so too must the life science industry.  Life science companies will need to adjust strategies to a world in which only true innovation and improved patient outcomes become the key determinant of value in the healthcare system. They will also need to develop commercial models which take account of the changing power balance between provider, payer and patients-all the while keeping a watchful eye on the competitive landscape for the incursion of non-traditional players with whom they will increasingly compete-or partner- to deliver patient-centred products and services. Meanwhile, scrutiny of high prices for speciality drugs and advanced technologies is increasing, impacting the ability of life science companies to bring much needed innovation to patients.How will the industry’s future unfold?The FT Global Pharmaceutical and Biotechnology Conference, now in its 33rd successful year, is a must-attend for industry executives, thought leaders and investors wishing to keep abreast of the emerging trends reshaping the global healthcare and life sciences industry.Download the Event Brochure here >>FT-Global-Pharmaceutical-and-Biotechnology-Conference-201583d0db339ee711a15e01cca11b6d5bd8MM/DD/YYYY

Keynotes (5)

Severin Schwan

Severin Schwan

Chief Executive Officer
Roche Group

In March 2008 Severin Schwan was appointed CEO of the Roche Group and became a member of the Roche Board in 2013.

Prior to this, Dr Schwan was CEO of Roche Diagnostics, the Roche Group’s global diagnostics business. He also served as regional head of the Roche Diagnostics business for Asia-Pacific from 2004, based in Singapore. This followed various management postings to Belgium, Germany and Switzerland at Roche, beginning with his initial role at Roche Basel in 1993 as a finance officer. Dr Schwan has a degree in Economics and a doctorate in Law.

SeungSuh (Stanley) Hong

SeungSuh (Stanley) Hong

President & CEO
Celltrion Healthcare

Stanley Hong, President and CEO of Celltrion Healthcare, joined Celltrion group when it was founded in 2002 and has played an important part in its development and success. Dr Hong was President of Research & Development at Celltrion, Inc., where he was responsible for all aspects of R&D including product discovery, biosimilar development, and nonclinical and clinical trials. His team led the successful development of REMSIMA™, the world’s first biosimilar, and gained approval for the product in Korea, Japan, Canada, and across the European Union. Dr Hong was also responsible for other biosimilars in development at Celltrion, and has presented data on biosimilars at national and international medical meetings.Dr Hong has extensive experience in the development of biopharmaceutical products and industrial enzymes. Before joining Celltrion, he spent 20 years at Samyang Genex Corporation in South Korea where he was responsible for R&D in biotechnology, and where he gained experience in the area of cell culture-based pharmaceutical development. While at Samyang Genex Corp he developed several products that were later successfully commercialised. Dr Hong studied Enzymology and Biochemical Engineering at Seoul National University in Korea, and received a PhD from the same institution in 1990. He spent two years at the University of Wisconsin as a Postdoctoral Fellow in the Department of Bacteriology and the School of Pharmacy. Dr Hong has published 41 papers and holds 120 Korean patents and 20 international patents.

Jim O'Neill

Jim O'Neill

Chair
The Review of Antimicrobial Resistance

Jim O’Neill is an internationally published economist, and until 2013 was Chairman of Goldman Sachs Asset Management, having previously been the organisation’s Head of Economic Research. Mr O’Neil is particularly well-known for his work in relation to developing economies, having been one of the earliest (and most prominent) economic commentators to identify the enormous potential for growth by middle income countries during the first half of the 21st century. In 2001, Jim published his influential Building Better Global BRICs research paper, which was credited with coining the BRIC (Brazil, Russia, India, and China) acronym, and foresaw the radical shift in global economic power away from the established western economies towards these rapidly-expanding economies. Since then, Mr O’Neill’s work has shone a light on the development of the next wave of emerging economies, including the ‘MINTs’ – Mexico, Indonesia, Nigeria and Thailand. This deep understanding of global patterns of growth and economic development means Mr O’Neill is especially well-placed to understand the broad range of international interests and interdependencies at play within the issue of rising resistance to antimicrobial drugs.

Jean-Christophe  Tellier

Jean-Christophe Tellier

Chairman and Chief Executive Officer
UCB

Jean-Christophe Tellier joined UCB in 2011 and became Chief Executive Officer in January 2015. He is a member of the company’s Board of Directors. He previously successfully led UCB’s BioBrands and Solutions division as Executive Vice President. Mr Tellier is an experienced global leader who has built a distinguished 25-year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world. He trained as a Medical Doctor and specialized in rheumatology

David Haslam, CBE

David Haslam, CBE

Chair
National Institute for Health and Care Excellence (NICE)

David Haslam is Chair of the National Institute for Health and Care Excellence (NICE). He is also a Fellow of the Royal College of GPs, Fellow of the Faculty of Public Health, Fellow of the Academy of Medical Educators, Fellow of the Royal College of Physicians, Professor of General Practice in the University of Nicosia, and Visiting Professor in Primary Health Care at de Montfort University, Leicester. He was a GP in Ramsey, Cambridgeshire, for 36 years and previous roles also include: Past-President of the British Medical Association, Past-President of the Royal College of General Practitioners, Chair of the NHS Evidence Advisory Committee, Co-Chair of the NHS Future Forum Information subgroup, an Expert Member of the NHS National Quality Board, Chair of the NQB Quality Information Committee, and National Clinical Adviser to both the Care Quality Commission and the Healthcare Commission. He was Chairman of Council of the RCGP from 2001 to 2004, and was also a member of the NHS Modernisation Board, Vice Chairman of the Academy of Medical Royal Colleges, a member of the Postgraduate Medical Education Training Board, a member of NHS Medical Education England, a member of the RCP’s Future Hospital Commission, and Co-Chair of the MMC Programme Board from 2006-9. Professor Haslam has written 13 books, mainly on health topics for the lay public and translated into 13 languages, and well over a thousand articles for the medical and lay press. He was awarded the CBE in 2004 for services to Medicine and Health Care, and a Doctorate from Birmingham University in 2014

fallback

Speakers (37)

Ronald Brus

Ronald Brus

Founder and CEO
myTomorrows

Ronald Brus is CEO of myTomorrows, a company he founded in 2012 to provide doctors and patients with access to drugs in development. Before myTomorrows, Mr Brus worked at Crucell for 14 years. He was CEO from 2004 until the company was acquired by Johnson & Johnson in 2011. myTomorrows provides physicians and patients with a high unmet medical need, and for those that are excluded from clinical trials, access to innovative drugs in development. Together with a global team of physicians, biomedical specialists, pharmaceutical insiders, regulatory and legal experts, myTomorrows identifies innovative drugs, informs physicians and patients and facilitates requests for access to these drugs in development. myTomorrows designs, implements and conducts global Early Access Programmmes through its internet-based platform. The platform ensures rapid deployment of knowledge, infrastructure and technology to optimize access for physicians and their patients in addition to collecting real-world data.myTomorrows focuses on the following disease areas: oncology, neurology, psychiatry and rare diseases.

Lisa Urquhart

Lisa Urquhart

Editor
EP Vantage

Lisa Urquhart is editor of EP Vantage, a leading online news and analysis service covering the pharma, biotech and medtech industries. A journalist with more than a decade of industry experience, Lisa joined EP Vantage from the Financial Times, where she held a variety of positions, including biotechnology correspondent.  Lisa is an active contributor to industry panels and articles and has commented on the pharmaceutical industry on both television and radio, focusing on business models, M&A and R&D strategies and innovation. In 2011 she was part of the EP Vantage team that won European Mediscience Commentator of the Year.

Steve Miller

Steve Miller

Senior Vice President and Chief Medical Officer
Express Scripts

Steve Miller is Senior Vice President & Chief Medical Officer, Express Scripts, a position he has held since 2006, and is actively involved in developing the company’s clinical programs and advocating for more affordable and accessible healthcare in the United States. He is a leader in the promotion of legislation to create a pathway at the US Food and Drug Administration for the regulation of biosimilars. Prior to joining Express Scripts in 2005, Dr Miller was the Vice President and Chief Medical Officer at Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis, Missouri. He received his medical degree from the University of Missouri- Kansas City, and he trained in the Pathology and Research fellowship at the University of Alabama at Birmingham, and in Cardiology at the University of California, San Francisco. Dr Miller also earned his MBA at the Olin School of Business at Washington University in St. Louis.

David Meeker

David Meeker

President and Chief Executive Officer
Genzyme,a Sanofi company

David Meeker was appointed President and Chief Executive Officer of Genzyme in October 2011. Genzyme is a global biotechnology company committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs. Dr Meeker oversees and provides the vision for the company’s two business units – Rare Diseases and Multiple Sclerosis - as well as its long-standing relationships with patient communities and dedicated workforce of 10,000 employees. In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions.As Chief Operating Officer, he played an important role in the integration with Sanofi. Dr Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current rare disease portfolio. Prior to joining Genzyme, Dr Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters. Dr Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

Albert Bourla

Albert Bourla

Group President
Pfizer Innovative Health

Albert Bourla is the Group President of Pfizer Innovative Health at Pfizer Inc., and is a member of the Company’s Executive Leadership Team.  Pfizer Innovative Health includes six business groups: Consumer Healthcare, Inflammation & Immunology, Internal Medicine (neuroscience and pain, and cardiovascular and metabolic), Oncology, Rare Disease and Vaccines It also includes Pfizer’s Global Health and Value organization, which is focused on demonstrating the value of innovation and supports access to Pfizer medicines and vaccines. Mr Bourla has more than twenty years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Before assuming his current role, he was the Group President of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare Business. Previously, he was President and General Manager of Pfizer’s Established Products Business, where he led the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio. Mr Bourla joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of US Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East and in 2009, he assumed additional responsibilities for Asia and Pacific. Mr Bourla is a Doctor of Veterinary Medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. 

Jean-Paul Clozel

Jean-Paul Clozel

CEO
Actelion Pharmaceuticals

Jean-Paul Clozel is a Cardiologist. He was educated in France, with further training in, pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco. After eleven years as a clinician, Dr Clozel decided to move to applied research. He spent 12 years at F. Hoffmann-La Roche Ltd, during which time he was responsible for the selection of the first T-channel blocker. He also participated in the characterisation of renin inhibitors as well as several endothelin receptor antagonists such as bosentan and clazosentan. Overall, the group he was heading discovered seven compounds that entered clinical trials. During his 25-year-career in cardiology, he has published widely in peer-reviewed medical and scientific journals. At the same time, his passion has remained unchanged: being involved as closely as possible in bringing innovative medicine to "his" patients. He has developed various, novel experimental models allowing the differentiation of these drugs, work honoured with the 1997 Hoffmann-La Roche Research Prize. In 2007, he was nominated Professor at the Collège de France in Paris, France (Chair of Technical Innovation). At the end of 1997, Dr Clozel founded Actelion, together with his wife, Martine, and work colleagues and friends, Walter Fischli, Thomas Widmann and André J. Mueller. First mainly focusing on Research and Development, he became CEO of the company and took Actelion public in April 2000. A key achievement of Dr Clozel is building Actelion from a start-up to a multi- billion market capitalisation company in a highly competitive and complex sector. Dr Clozel has been the driving force that enabled Actelion to become one of the biotechnology industry’s most recognized global success stories.

Seth Berkley

Seth Berkley

Chief Executive Officer
GAVI Alliance
David Redfern

David Redfern

Chief Strategy Officer
GlaxoSmithKline

David Redfern was appointed Chief Strategy Officer of GSK in May 2008.   He is a member of the Corporate Executive Team and reports to the CEO. Mr Redfern is also Chairman of ViiV Healthcare Ltd.   ViiV was created in 2010 and is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the research, development and commercialisation of medicines to treat HIV.  In February 2015, Mr Redfern was appointed a non–executive director of Aspen Pharmacare Holdings Ltd., a South African listed healthcare company. Previously, he was responsible for the leadership of GSK’s business in Northern Europe from 2005-2008 and Central Europe from 2002-2005.  He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999.  Prior to Glaxo, Mr Redfern worked for PWC in London, Zambia and Paris.   

Mohammad Al-Ubaydli

Mohammad Al-Ubaydli

Founder and CEO
Patients Know Best

Mohammad Al-Ubaydli is Founder and CEO of Patients Know Best and has over 15 years of experience in medical software. He trained as a physician at the University of Cambridge; worked as a staff scientist at the National Institutes of Health; and was a management consultant to US hospitals at The Advisory Board Company. He is the author of seven books, including Personal health records: A guide for clinicians and Streamlining Hospital-Patient Communication: Developing High Impact Patient Portals. He is also an Honourary Senior Research Associate at UCL Medical School for his research on patient-controlled medical records. In 2012 he was elected an Ashoka Fellow as a social entrepreneur for the contributions he has made to patient care.

Andrew Ward

Andrew Ward

Energy Editor
Financial Times

Andrew Ward is the FT’s Energy Editor, leading global coverage of the oil and gas industry, power generation and related policy and geopolitical issues. Before taking up his current role in June 2016, Ward was Pharmaceuticals Correspondent, reporting on life sciences, medical technology and healthcare.

Prior to this, Ward was UK News Editor, leading the news desk responsible for the FT’s coverage of UK politics, policy and economics. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania.

Ward has also been the White House correspondent, during which role he covered the George W. Bush administration and the 2008 presidential election campaign. Before moving to Washington, Ward covered business and politics in the US south-east as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea.

Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. Ward received his B.A. in Politics and Modern History from the University of Manchester, UK.

Follow Andrew Ward on twitter: @andrew_ward1

Shaun  Grady

Shaun Grady

Vice President, Business Development Operations
AstraZeneca

Shaun Grady is Vice President, Business Development, Global Product and Portfolio Strategy (GPPS) of AstraZeneca, with  global responsibility for Business Development Operations. In this role he leads the company’s transaction execution, due diligence and alliance and integration management function including externalisation, licensing and partnering, M&A, and divestments. Mr Grady was appointed to his current role in 2013 with the creation of the Global Product and Portfolio Strategy (GPPS) unit. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10). Mr Grady originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger of Zeneca from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca. Mr Grady has worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Mr Grady also worked on AstraZeneca’s acquisition of Cambridge Antibody Technology (CAT), led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the Diabetes Alliance. In addition, he has spent time in the US business managing the legal function and also completed a two year secondment to HR, leading a global People Strategy change project.

Tuomo Pätsi

Tuomo Pätsi

President, Europe, Middle East, Africa
Celgene

Tuomo Pätsi was appointed as President of Celgene for Europe, Middle East and Africa (EMEA) in September 2014. Prior to this, he served as Corporate Vice President with responsibility for the South Europe Region (France, Italy, Spain, Portugal, Greece, Turkey, Middle East and Africa).Since joining Celgene , Mr Pätsi has held several positions, including General Manager, Regional Vice President for the North Europe Region, and Head of European Marketing. He has been instrumental in building Celgene’s EU commercial organisation and establishing Celgene affiliates in several European countries. From 2010 to 2012, Mr Pätsi served as Vice President Europe at Human Genome Sciences (HGS), a specialty pharmaceutical company. In this role, he helped establish the European organisation. Following the acquisition of HGS by GlaxoSmithKline, he took the opportunity to return to Celgene. Prior to first joining Celgene in 2006, Mr Pätsi had roles of increasing responsibility at Amgen in Europe and at the company’s global headquarters in California. A registered pharmacist, he began his career as a pharmacologist in a research centre before moving into the pharmaceutical industry in 1990.

Jan van de Winkel

Jan van de Winkel

President and Chief Executive Officer
Genmab

Dr van de Winkel is a Co-Founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr van de Winkel has over 20 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 40 patents and pending patent applications. Dr van de Winkel holds a Professorship in Immunology at Utrecht University. He is Chairman of the Board of Directors of Regenesance and member of the Board of Directors of ISA Pharmaceuticals, Celdara Medical and Forward Pharma, member of the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. He holds M.S. and PhD. degrees from the University of Nijmegen.

Rady Johnson

Rady Johnson

Executive Vice President, Chief Compliance and Chief Risk Officer
Pfizer

Rady Johnson is Executive Vice President and Pfizer’s Chief Compliance and Risk Officer. He has overall responsibility for the company's corporate compliance programmes and reports to the Chief Executive Officer. Mr Johnson has been with Pfizer since 1994 and has served in a number of leadership positions, including as Associate General Counsel for the company's Specialty Care Business Unit and as Head of the Global Product and Regulatory Law practice group. Prior to joining Pfizer, Mr Johnson was a member of Hogan & Hartson, LLP’s food and drug law practice group based in Washington D.C. and also worked as a Certified Public Accountant and Senior Auditor for Arthur Anderson & Co. Mr Johnson graduated from the University of Richmond and Georgetown University Law Center.

Eric Cornut

Eric Cornut

Chief Ethics, Compliance and Policy Officer
Novartis

Eric Cornut has been Chief Ethics, Compliance and Policy Officer of Novartis since August 2014. In this role, Mr Cornut leads the Integrity & Compliance and the Public Affairs functions where he is responsible for strengthening compliance and public policy for Novartis. He also serves as the Chairman of Novartis Group Japan.

Previously, Mr Cornut served as Chief Commercial Officer (CCO) of Novartis Pharmaceuticals where he was responsible for Global Product Strategy and Commercialization. This included Medical Affairs, Pricing and Market Access, Health Economics and Outcomes Research as well as Business Development & Licensing. In this role Mr Cornut transformed the organisation to be more patient centric. He also successfully brought innovative therapies in dermatology and heart failure to patients. Earlier, he led Pharma Region Europe for six years where he oversaw the operations of affiliates in 35 countries with approximately 9,000 associates. Under Mr Cornut’s leadership, his teams successfully launched 13 new products and achieved more than US$ 7 bn in sales despite the challenging economic situation in Europe. Mr Cornut began his career at Novartis predecessor company, Ciba-Geigy, in 1989 and played a key role in the global merger of Ciba-Geigy and Sandoz in 1996. Following this, he assumed the role of Chief Executive Officer (CEO) Novartis Netherlands and he subsequently became President and CEO of Novartis France in 2000. Mr Cornut has a Doctoral degree in Law from the University of Basel, Switzerland, and a Master of Law degree from the University of California, Berkeley, in the United States.

Perry Siatis

Perry Siatis

Vice President, Biologics Strategy Development
AbbVie

Perry Siatis is Vice President, Biotherapeutics and Legal for AbbVie. He has responsibility for the

company’s biological product strategy and several groups within the legal department, including commercial, international, manufacturing, securities and benefits lawyers and legal operations. Prior to AbbVie’s separation from Abbott, Mr Siatis was Counsel in the IP Litigation group, then as Senior Counsel, then  Division Counsel in the IP Litigation department before becoming  Divisional Vice President, Intellectual Property Strategy of Abbott. Prior to joining the company, Mr Siatis practiced commercial and IP litigation at DLA Piper LLP.  He earned a Bachelor's degree in accounting from George Mason University and a Juris Doctorate Degree from Brigham Young University.

Karl Claxton

Karl Claxton

Professor of Economics
Cetre of Health Economics, University of York

Karl Claxton is a Professor in the Department of Economics and the Centre for Health Economics at the University of York where he leads the economic evaluation component of the Health Economics MSc. He is a past Co-Editor of the Journal of Health Economics and for many years held an adjunct appointment at the Harvard School of Public Health. He was a founding member of the NICE Technology Appraisal Committee and continues to contribute to the development of the NICE Guide to the Methods of Technology Appraisal.  He has contributed in a number of ways to recent policy debates such as pharmaceutical pricing and innovation.

Suzanne Sysko Clough

Suzanne Sysko Clough

Founder and Chief Medical Officer
WellDoc Inc.

Suzanne Sysko Clough is an endocrinologist and the Co-Founder and Chief Medical Officer of WellDoc, a healthcare technology company that productized the first prescription mobile health app, BlueStar. As WellDoc’s CMO, Dr Clough led the team responsible for the clinical and behavioural algorithm design and architecture of WellDoc’s chronic disease platform. Additionally, as a member of the executive management team, she has helped guide the company through the process of conducting and publishing randomized controlled clinical trials with demonstrated efficacy and improved health outcomes, receiving FDA clearance and obtaining reimbursement for its clinical software.

Ameet Nathwani

Ameet Nathwani

Executive Vice President, Group Chief Medical Officer and Global Head of Medical Function
Sanofi

Ameet Nathwani was appointed as Executive Vice President, Group Chief Medical Officer and Global Head of Medical Function of Sanofi in May, 2016. Dr Nathwani is responsible for enterprise-wide medical, patient safety, medical quality assurance and ensuring the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organizations. A UK. citizen, born in Uganda and educated in the UK, Dr Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over a period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability. Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.

Pascale Witz

Pascale Witz

Executive Vice President, Global Divisions and Strategic Development
Sanofi

Pascale Witz is the Executive Vice President, Global Divisions & Strategic Development of Sanofi and a Member of its Executive Committee.

She joined Sanofi in 2013 and leadsa portfolio of businesses totaling €15 billion, including Diabetes, Oncology, Immuno-inflammation, Cardiovascular and Consumer Healthcare.

Previously, she worked at GE for 17 years, most recently serving as President & CEO of GE Healthcare’s Medical Diagnostics business. She started her career in research before moving into marketing at Becton Dickinson in 1991.

In 2014, she was listed as one of Fortune’s Most Powerful Women in EMEA. She is also engaged in the Women’s Forum. She holds a Master’s degree in Life Sciences from INSA Lyon and an MBA from INSEAD.

Guido Rasi

Guido Rasi

Executive Director
European Medicines Agency (EMA)

Professor Guido Rasi was appointed as Principal Adviser in Charge of Strategy of the European Medicines Agency in 2014. Prior to this, from 2011 to 2014 he was the Executive Director, and from 2008 to 2011 a Member of its Management Board of the Agency.   He also held the post of Director-General of the Italian Medicines Agency from 2008 to 2011, and was a member of the Agency’s Management Board from 2004 and 2008. This followed a prior career in academia. Professor Rasi was appointed Professor of Microbiology at the University of Rome 'Tor Vergata' in 2008. From 2005 to 2008 he was Director of the Institute of Molecular Medicine of the National Research Council in Rome and from 1990 to 2005, he worked at the Institute for Experimental Medicine of the National Research Council, Italy. He also had teaching and research experience at the University of California, Berkeley in 1999. Professor Rasi holds a degree in Medicine and Surgery, with specialisations in Internal Medicine, Allergology and Clinical Immunology from the University of Rome.  From 1978 to 1990, he worked as a physician in hospital based, research and private practice. He is author of more than 100 scientific publications.

Alpna Seth

Alpna Seth

Vice President, Head of Biosimilars
Biogen

Alpna Seth is Vice President and Head of the Biosimilars Business Unit at Biogen. She joined the company in 1998 and has held various leadership roles across marketing, strategy and portfolio planning, and R&D, including leading the company’s first gene therapy programme. Prior to leading Biogen’s Biosimilars Business Unit, she was Programme Executive and Vice President and Global Head of TECFIDERA®. In that role, she successfully led pivotal Phase III read‐outs, regulatory filings, marketing approvals, and commercial launches for the brand worldwide. Dr Seth previously held the role of Managing Director for Biogen’s office in India, setting up the affiliate from the ground up. Prior to joining Biogen, she was a management consultant in the healthcare industry. She received her PhD. in Biochemistry and Molecular Biology from the University of Massachusetts Medical School. She conducted her post-doctoral research at Harvard University in Immunology and Structural Biology. Dr Seth is also a graduate of Harvard Business School’s Advanced Management Program. She routinely serves as a guest lecturer at Harvard and Tufts Universities.

Natalie Woodford

Natalie Woodford

Senior Vice President,Talent.Leadership & Organisational Development
GlaxoSmithKline

Natalie Woodford was appointed Senior Vice President, Talent, and Leadership & Organisation Development of GlaxoSmithKline (GSK) in October 2010.  In this role, she is responsible for leading a function that identifies and develops the critical capabilities GSK requires from its workforce both now and in the future, and to ensure the company has the right people to execute business strategy in line with its values.  Since joining GSK in 1992, she has worked across the company in roles which include Head of Global Talent, HR Business Leader for Pharmaceuticals in France and the UK, as well as HR roles in Manufacturing, Corporate HR, and Consumer markets across Europe. Ms Woodford started her career in HR in the Ford Motor company and then worked as a recruitment consultant. She has a degree in Law from Brasenose College, Oxford.

Dame Sally Davies

Dame Sally Davies

Chief Medical Officer
UK Department of Health

Dame Sally Davies is the Chief Medical Officer for England and also advises the UK Government.  She holds responsibility for Research and Development, and is the Chief Scientific Adviser for the Department of Health.

The Chief Medical Officer is the independent advisor to the UK Government on all medical matters, with particular responsibilities regarding Public Health.  In particular, she provides professional leadership for Directors of Public Health in England.  

Dame Sally has been actively involved in NHS R&D from its establishment.  As Director-General she established the National Institute for Health Research (NIHR) with a budget of £1 billion.  

Dame Sally was awarded a DBE (Dame Commander of the British Empire) in the New Year Honours 2009 for services to medicine and in 2011 she was conferred as Emeritus Professor at Imperial College London. She was elected a Fellow of the Royal Society in May 2014 for her outstanding contribution to science through her exceptional leadership in health research.

Natacha Theytaz

Natacha Theytaz

Chief Audit & Risk Advisory Executive
Roche Group

Natacha Theytaz is the Chief Audit & Risk Advisory Executive for Roche Group, a position she has held since 2010. She is responsible at the group level for internal audit, risk management, internal investigations and financial compliance. In this role, she regularly presents to different committees of the Board of Directors on topics related to risk, compliance, governance and process improvements covering the pharmaceutical and diagnostics divisions, as well as all Group Functions.  Prior to joining Roche, she has gathered various experiences in different fields and industries. She has worked as a strategic consultant with Roland Berger, as an advisor for the World Trade Directorate at the Swiss State Secretariat for Economic Affairs, as well as a senior manager at Ernst & Young. She was also a Board member of the Swiss Institute of Internal Auditing. She holds a BA in Social Sciences, a Master’s degree in Advanced European studies and a Doctorate in Business Administration.

Jenny Alltoft

Jenny Alltoft

Global Biosimilars Lead
Pfizer Essential Health

With 30 years’ experience in pharmaceutical portfolio management, Jenny Alltoft has a proven track record covering all aspects of a product’s lifecycle, including from early R&D to loss of exclusivity. She is a skilled coach and authentic leader, dedicated to unlocking the potential in organizations and team members. In her current role as Global Leader of Pfizer’s Biosimilars business, she leads global strategy, alliance management, M&A, market development and commercialization of biosimilars.  Prior to this role, she was General Manager for Pfizer’s Established Products business unit in Australia and New Zealand, managing a portfolio of more than 150 branded and generic medicines used in general practice and hospital settings. Additional career highlights include successfully managing and growing a blockbuster antihypertensive therapy and leading the global team responsible for developing the commercialization strategy for a smoking cessation therapy. Ms Alltoft’s ability to incorporate consumer insights into marketing strategies contributed to a leadership role in establishing Pfizer’s Patient and Marketing Centers of Expertise.  In 2004, Ms Alltoft was the recipient of the Healthcare Business
Women’s Association Rising Star Award, reflecting her strengths and achievements in healthcare.

Pascale Richetta

Pascale Richetta

Vice President,Western Europe & Canada Operations
AbbVie

Pascale Richetta is Vice President of Operations for AbbVie in Western Europe and Canada. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. AbbVie’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Ms Richetta was with Abbott Laboratories for nine years, first as General Manager in Belgium and subsequently as Divisional Vice President, Europe North before her appointment as Vice President in 2009. Before joining Abbott, she was Vice President of Operations, France for GlaxoSmithKline, where she was responsible for Central Nervous System, Urology, Vaccines and Customer Services. She had previously held various positions in both France and Europe for GSK – working in the Neuro-psychiatry, Gastrointestinal and Cardio-pulmonary therapy areas. Prior to GSK she worked at Ipsen Beaufour and Servier.Pascale Richetta is a physician (Poitiers University, France). She is a member of the European Steering Committee on Sustainable Healthcare as well as EFPIA Executive Committee, and belongs to the EFPIA Greece and Spain Task Forces. She is also an active member of EBE (European Biopharmaceutical Enterprises) and EuropaBio (the European Associations for Bioindustries).

Andrea Ponti

Andrea Ponti

Partner
GHO Capital Partners

Andrea Ponti has 30 years of investment banking experience, focusing on healthcare since 1996. He is a Founding Partner at Global Healthcare Opportunities, or GHO Capital, which was established in 2014 as a specialist healthcare investment adviser based in London.  Previously, Mr Ponti created both JP Morgan’s and Goldman Sachs’ European investment banking healthcare franchises, advising on some of the most significant mergers and acquisitions for leading pharmaceutical, medical device and hospital companies, but also advising emerging companies and private equity on M&A and debt or equity financing. Over the last five years he was Vice Chairman of European Investment Banking and Global Co-Head of Healthcare at J.P. Morgan. Prior to that, Mr Ponti was at Goldman Sachs, where he was Partner, Managing Director, Head of European Healthcare, Consumer and Retail and also Co Global Head of Healthcare. He covered a variety of roles during his time at the firm, including member of the firm-wide Commitments Committee. Mr Ponti sits on the board of Cell Medica and holds a BA in Economics with Highest Honours from the University of North Carolina at Chapel Hill, where he is also a member of the Arts and Sciences Foundation Board of Directors.

Guy Yeoman

Guy Yeoman

Vice President, Patient Centricity
AstraZeneca

Guy Yeoman qualified in medicine and worked in the NHS in the 1990’s.  He spent five years at GlaxoSmithKline in clinical development, medical affairs and project management before moving to develop UK medical affairs and market access for a French company. He has spent the last seven years with AstraZeneca, initially as the UK Medical Director before moving to Asia to build an integrated medical affairs capability across Asia Pacific.  More recently Dr Yeoman established a new global Medical Evidence Centre focussed on delivering integrated evidence, external science and publications. He is now Vice President, Patient Centricity at AstraZeneca where his team focuses on the fast and efficient delivery of patient centric medicines and services. 

John Kallend

John Kallend

Senior Vice President, Director of Manufacturer Relations and Services
Walgreens Boots Alliance

John Kallend is Senior Vice President, Director of Manufacturer Relations and Services, Walgreens Boots Alliance. In this role, he is responsible for the relationship with pharmaceutical and healthcare manufacturers, and the development and selling of services for manufacturers. He is also responsible for two synergy workstreams for Walgreens Boots Alliance Development GmbH.  Prior to joining Walgreens Boots Alliance, Mr Kallend held a number of positions in the pharmaceutical retail industry including General Manager of Alloga; Director of Regional Wholesale Alliance UniChem and Managing Director AU Portugal. He also worked in the logistics industry for eight years in an operational and commercial role. Mr Kallend has a BA Honours degree from the University of Birmingham.

Stephen Caddick

Stephen Caddick

Director of Innovations
Wellcome Trust

Stephen Caddick joined the Wellcome Trust in June 2015 and leads the Innovations division. He is also Professor of Chemical Biology at University College London (UCL). Previously, he was a member of UCL’s Senior Management Team as Vice Provost (Enterprise & London) and led UCL’s activities in enterprise and innovation including knowledge and technology transfer, student enterprise, academic consultancy, industry partnerships and continuing professional development. He also led the development of UCL’s new campus, UCL East on the Queen Elizabeth Olympic Park.  He has been Head of Department of Chemistry at UCL and has been Non-Executive Director of UCL Business, Chair of UCL Consultants, and Chair of the Bloomsbury Bioseed Fund and is a member of MRCT Technology Science Advisory Board. He is a member of the Royal Society Science, Industry and Translation Committee and has previously been a member or chair of numerous EPSRC, BBSRC, and MRC funding committees. Professor Caddick is Co-Founder of Synthetic Pages, an open access website, and Thiologics, an antibody-drug conjugate (ADC) biotech spin-out company. He led the development of the chemical biology strategy and facilities for the Francis Crick Institute. He has published over 160 peer-review publications and his laboratory focuses on chemical modification of proteins and antibodies for development of therapeutics and diagnostics.

Finn Børlum Kristensen

Finn Børlum Kristensen

Seceteriat Director
European Network for Health Technology Assessment (EUnetHTA)

Finn Boerlum Kristensen has been Chairman of the Executive Committee of the Executive, EUnetHTA, (www.eunethta.eu<http://www.eunethta.eu/) since 2010. He previously served as Head of the Coordinating Secretariat, EUnetHTA in the Danish Health and Medicines Authority (DHMA), Copenhagen, from 2006. He was as Adjunct Professor in Health Services Research and Health Technology Assessment at University of Southern Denmark from 1999. From 1997-2009, since its establishment, Dr Kristensen was also Head of the Danish Centre for Health Technology Assessment (DACEHTA). A Primary care physician and specialist in public health, Dr Kristensen served as Chairman International Network of Agencies for Health Technology Assessment (INAHTA) from 2003-2006; as Board Director, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from  2011-2013, and as. Chairman of ISPOR HTA Council from 2013. He also served as the Editor of Health Technology Assessment Handbook in 2007 and as Chief Editor of three peer reviewed publication series from DACEHTA from 1998-2009. His writings have appeared in numerous scientific publications relating to HTA, health services research, epidemiology and policy analysis. Dr Kristensen has a degree in Medicine and a Doctorate in Epidemiology.

Reynold W. (Pete) Mooney

Reynold W. (Pete) Mooney

Global Managing Director, Life Sciences and Health Care
Deloitte

Reynold W. (Pete) Mooney is a senior strategy consulting principal and is currently the Global Managing Director for the Life Sciences and Health Care industry group for Deloitte Touche Tohmatsu Limited (Deloitte). In this role, he is responsible for building practice capability around the world, ensuring consistent service offerings across lines of business, and works closely with Deloitte’s network of member firms in serving clients, governments, Ministries of Health, NGOs, and other constituencies. He is also a principal in Deloitte’s US member firm. Mr Mooney is consulted frequently on global health issues and by pharmaceutical, biotechnology, medical device and other companies that supply the industry. He is a frequent speaker and author on industry topics. Over the course of his thirty-five year career with Deloitte member firms, he has served a number of very significant client relationships across a diverse set of issues, industry sectors, geographies and cultures. A manufacturing professional by background, his approach to strategy is grounded in solid operations management concepts. He gravitated to the life sciences sectors while working with several European chemicals conglomerates in the early 1990s, and currently works with a diverse set of leading life sciences and health care clients globally in both the public and private sectors.

Mr Mooney received a BA from Washington & Jefferson College, where he currently serves as a Trustee, and an MBA. from the Katz School of Business, University of Pittsburgh.

Andrew Edge

Andrew Edge

Partner, Head of Corporate
Stephenson Harwood

Andrew Edge is head of the Stephenson Harwood Corporate department. He has advised in the life sciences sector for over 20 years on public and private M&A, joint ventures and public and private fundraisings, including IPOs. Mr Edge has acted for a wide range of life sciences companies including for BTG on its acquisitions of PneumRx, EKOS and Biocompatibles International, Piramal on the $3.8bn disposal of its Domestic Formulations business to Abbott, Northland on the AIM IPO of Evgen Pharma and Shield Therapeutics on its recent attempted London main market IPO. Mr Edge is ranked both as a leading M&A and life sciences lawyer by Chambers UK as well as being listed as one of The Lawyer magazine's "Hot 100" lawyers for 2012.  He has also appeared in the Super Lawyers list of top lawyers from 2013 to 2015.

Philipp Gutzwiller

Philipp Gutzwiller

Global Head Healthcare
Lloyds Bank

Philipp Gutzwiller is leading the coverage of global corporate clients in the healthcare sector for Lloyds Bank. He has accumulated over 15 years as a corporate finance advisor and banker to the pharmaceutical industry. Before joining Lloyds Bank, Philipp worked for both bulge-bracket and boutique investment banks with a focus on M&A advisory in the broader healthcare industry. He started his career in the Corporate Finance Division of Roche as a financial controller and later worked in the firm’s corporate M&A department. Mr Gutzwiller holds a Master’s Degree in Finance and Economics from the University of Basel, Switzerland.

James Wright

James Wright

Tax Lead Partner, Healthcare & Life Sciences
Deloitte UK

James Wright is an international tax partner based in London with more than 20 years’ experience advising large multinationals. He is a member of Deloitte’s UK leadership team and is the tax industry lead for Health and Life Sciences, with responsibility for developing Deloitte’s UK Health and Life Sciences Practice. He has also spent time working in Sydney and has since retained strong Australian connections. Mr Wright’s’ clients include several large life science companies and he has particular experience advising on cross-border mergers, acquisitions, disposals, reorganisations, business model change and financing.

Jeremy Morgan

Jeremy Morgan

International Vice President, Diabetes
Lilly

Jeremy Morgan is International Vice President, Diabetes, at Eli Lilly and Company, overseeing Lilly’s diabetes business in Canada and Europe. Mr Morgan is a Board Member of The European Association for Bio-Industries (EuropaBio).. Lilly has been a global leader in diabetes since 1923, when it introduced the world's first commercial insulin. Today, Lilly is building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. During his 28 year career with Lilly, Mr Morgan has held several leadership positions across many geographies, including Australia and New Zealand, Turkey, France, the UK, and the USA. Prior to his current role, he served as General Manager of Lilly’s German affiliate for three years, latterly also covering Austria and Switzerland. Mr Morgan graduated with an Honours Degree in Applied Biology from the University of Coventry, UK.

fallback

Presentations

Philipp Gutzwiller, Lloyds Bank - 'M&A - A BLUEPRINT FOR HEALTH?'

fallback

Agenda - 16th Nov

  • 9:00am
    Chairman Welcome

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:05am
    Keynote Address

    Severin Schwan, Chief Executive Officer, Roche Group

  • 9:30am
    Panel: Market Access: Towards a Sustainable Solution to the Challenge of Rising Medicine Costs

    Market access is about to get much more challenging for life science companies in the years ahead. Just as advances in science are yielding a rich harvest of biological based medicines that promise to raise the standards of treatment for patients, drug companies are losing their ability to price these medicines at will. In the US, scrutiny of high drug prices is increasing; the possibility of joint EU procurement of drugs has been the subject of recent discussions in the European Parliament, and calls for curbs on high drug prices can be expected to increase in the developed world as populations age and diseases such as cancer become more prevalent.

    • What is the solution to the current impasse regarding high drug costs between drug producers and payers?
    • How should the value of life science products be defined? Are we moving towards a more universal definition of value which takes account of the full cost of care?
    • Are premium prices the only way to sustain innovation-how could regulation and patents be reformed, and alternative payment and risk sharing systems be created to make drugs more affordable? 

    Steve Miller, Senior Vice President and Chief Medical Officer, Express Scripts

    Professor Karl Claxton, Professor of Health Economics, Centre of Health Economics, University of York

    Professor Finn Børlum Kristensen, Chairman of the Executive Committee, European Network for Health Technolgy Assessment (EUnetHTA)

     

  • 10:25am
    Networking Coffee Break
  • 10:50am
    Panel: Addressing Public Health Challenges and Unmet Medical Needs

    From antibiotic resistance to pandemics, to the rise of diabetes in both the developed and developing world and climate change related health conditions, what are the public health challenges the world is likely to see in the years ahead and how can they be addressed? The Ebola crisis has shown the way in what is achievable in terms of more rapid drug development.

    • What lessons have the industry and regulators learned from the Ebola experience that can be applied to ensure drugs are developed more efficiently in the future?
    • Is wellness and prevention the next big public health challenge?
    • With a greater proportion of drug development focus on premium products, how can we ensure unmet medical needs in area such as mental health and Alzheimer’s, for instance, are met?
    • What are the mechanisms and incentives to ensure these needs are addressed? 

    Sesssion Keynote: Jim O'Neill, Chair, The Review of Antimicrobial Resistance

    Panellists:

    Seth Berkley, CEO, GAVI Alliance

    Dame Sally Davies, Chief Medical and Chief Scientific Officer, UK Department of Health

    Professor Stephen Caddick,  Director of Innovations, Wellcome Trust

  • 11:45am
    Keynote Address and Interview

    David Haslam, Chair, The National Institute for Health and Care Excellence (NICE)

  • 12:10pm
    Lunch
  • 1:20pm
    Presentation: Taxing Times Ahead-Planning for Change

    Collaborations with external partners to improve R&D productivity, expansion in emerging markets, the provision of new patient orientated services to improve health outcomes and the search for growth through M&A-the many business model changes and growth strategies currently being undertaken or contemplated by life science companies will have major repercussion for their tax position and future profitability:

    • After the debate over inversions and the “double Irish”, can big pharma still shop around for the attractive tax domiciles, or are the days of such practices numbered?
    • Will the US system be reformed?
    • Why has pharma been at the centre of the tax debate?
    • What is the future of taxation in the pharma sector?

    James Wright, Tax Lead Partner, Healthcare & Life Sciences, Deloitte UK

  • 1:50pm
    Panel: M&A-A Blueprint for Health?

    The frenzied deal making which convulsed the life science industry last year show no signs of abating as companies continue in their quest for new growth and efficiencies in the face of rising pricing pressure, loss of patent protection and continuing productivity challenges. 

    • What forces have driven the M&A of the past year and are they here to stay?
    • What are the challenges of integration? Can they deliver increased value for shareholders and more efficient drugs for patients and payers?
    • As consolidation continues to reshape the sector, are we poised for a new era of growth, or is the recent spurt of M&A a ‘desperate resort to financial engineering to cover a broken business model?’
    • From asset swaps to carve outs, which M&A strategies will create winners and losers in the years ahead?

    Session Keynote: Philipp Gutzwiller, Global Head Healthcare, Global Corporates, Lloyds Bank

    David Redfern, Chief Strategy Officer, GlaxoSmithKline

    Shaun Grady, Vice President, Business Development Operations, AstraZeneca

    Andrea Ponti, Partner, GHO Capital Partners

  • 2:35pm
    Keynote Address

    David Meeker, President and CEO, Genzyme, a Sanofi company

  • 3:00pm
    Networking Coffee Break
  • 3:20pm
    Panel: What Next for Biotech? The Shape of Things to Come

    Can Europe build a biotech sector to rival that of the US? Boom times are back for US biotech with companies enjoying a surge in valuations and IPOs as investors buy into the growth story and as commercial dividends finally start to flow from the decoding of the human genome and other scientific advances.  The sector in the US is now mature with big biotech producing revenues to rival traditional big pharma. Valuations in Europe are rising too, but the market remains subdued with the industry missing out on the historic re-rating of the industry.

    • How can this transatlantic disparity be bridged?
    • Is the current biotech boom sustainable?
      • What is driving the surge in IPOs and valuations?Maturing genetic science or irrational exuberance?
    • Is the term biotech still relevant when Gilead is today bigger than GSK and Sanofi?
    • How can incentives for investment be increased and the funding environment improved?
    • How can Europe harness the historic opportunity to thrive in biotech?   

    Tuomo Pätsi, President, Celgene Europe, Middle East, Africa

    Jean-Paul Clozel, CEO, Actelion Pharmaceuticals

    Jan G.J. van de Winkel, President and Chief Executive Officer, Genmab

    Professor Sir Christopher EvansOBE, Chairman, Arthurian Life Sciences

    Lisa Urquhart, Editor, EP Vantage

    Andrew Edge, Partner, Head of Corporate, Stephenson Harwood

  • 4:20pm
    Panel: Biosimilars-Coming of Age

    The market for biosimilars is expected to expand considerably in the coming years as follow- on biologics gain favour with regulators, and as first generation blockbuster biologics lose patent exclusivity. Already established as part of the pharmaceutical market in Europe where a regulatory pathway was established in 2004, biosimilars are now expected to make inroads in the US market with the approval of the first products by the FDA this year. However, despite the considerable hope invested in these lower-priced products to moderate rising healthcare costs, prospects for commercial success and uptake remain uncertain:

    • Will the FDA pathway for biosimilars be sufficiently attractive to encourage prospective biosimilars manufacturers and generate robust competition, or will high costs, a challenging regulatory regime and uncertain revenue streams deter market entrants?
    • What will be the impact of product naming and prescriber notification?
    • How can market uptake be encouraged and trust be built with sceptical clinicians, payers, providers and patients?
    • What is the potential of biosimilars to save costs for healthcare systems? 

    Session Keynote: SeungSuh (Stanley)  Hong, President & CEO, Celltrion Healthcare

    Panellists:

    Alpna Seth, Vice President, Head of Biosimilars Business Unit, Biogen

    Jenny Altoft, Head of Biosimilars, Pfizer

    Jeremy Morgan, International Vice President, Diabetes, Lilly

    Perry Siatis, Vice President, Biologics Strategic Development, AbbVie

  • 5:20pm
    End of Day One

Agenda - 17th Nov

  • 9:00am
    Opening Remarks from the Chair

     Reynold W. (Pete) Mooney, Global Managing Director, Life Sciences and Health Care, Deloitte

  • 9:05am
    Keynote Address

    Jean-Christophe Tellier, Chairman and Chief Executive Officer, UCB

  • 9:30am
    Leadership, Skills and Change Management

    Natalie Woodford, Senior Vice President,Talent, Leadership & Organisational Development, GlaxoSmithKline

  • 9:55am
    Panel:Building Relationships with Patients and Doctors-The New Rules of Engagement

    Much is made of the growing role of the patient–the need for a customer rather than product focused approach to business and the changing power balance between life science companies, healthcare professionals and patients, yet how are companies defining and activating a patient-centric approach in practice? How are they organising to achieve this-to ensure the necessary culture change,skills formation and consideration of the patient perspective in all aspects of the business from development to launch and beyond? What do patients and doctors want and need from life science companies?  How will relations between life science companies and healthcare professionals evolve in the years ahead? How can life science companies build trust with HCPs and patients?

    Pascale Richetta, Vice President, Western Europe and Canada, AbbVie

    Pascale Witz, EVP Global Divsisions and Strategic Development,Sanofi

    Mohammad Al-Ubaydli, Founder and CEO, Patients Know Best

    Murray Stewart, Chief Medical Officer, GlaxoSmithKline

    Ameet Nathwani, Head of Global Medical Affairs, Novartis

     

  • 10:45am
    Networking Coffee Break
  • 11:05am
    Panel:Patient Services-Reinventing the Business Model?

    The emerging ‘beyond- the-pill’ strategies of life science companies -an increased focus on the health of patients beyond simply selling them drugs, to include such value-added service as telehealth, wellness programmes and improved chronic disease management may be a logical and inevitable step for an industry facing growing pressure to improve patient outcomes and lower costs, but how do life science companies fit into these new value-added structures? How will they compete against emerging new entrants including data-savvy companies in this emerging space? What services do patients want and how is the reimbursement regime evolving to support the provision of such services? What are the experiences of the companies already successfully providing patient services? Are patient services the new blockbuster for life science companies?

    Ronald Brus, President and Founder, myTomorrows

    Suzanne Sysko Clough, Founder and Chief Medical Officer, WellDoc

    John Kallend, Senior Vice President and  Director of Manufacturer Relations and Services , Walgreens Boots Alliance

    Guy Yeoman, Vice President, Patient Centricity, AstraZeneca

  • 11:55am
    Ethics-Managing Risk and the Cost of Compliance

    As regulators and regulations continue to “grow teeth,” life sciences companies will need to demonstrate that they have active and comprehensive compliance programs across their business and clinical operations, including commercial, R&D, and supply chain. How is the regulatory and risk environment evolving, and what are the potential future risks and compliance challenges for the industry? How can companies ensure compliance is more than a tick box exercise, and build a more ethical approach through the business? How are best-in-class companies dealing with and managing risk and regulatory uncertainty?

    Session Keynote: Rady Johnson, Executive Vice President, Chief Compliance and Chief Risk Officer, Pfizer

    Natacha Theytaz, Chief Audit & Risk Advisory Executive, Roche Group

    Guido Rasi, Principal Adviser in Charge of Strategy, European Medicines Agency

    Eric Cornut, Chief Ethics, Compliance and Policy Officer, Novartis  

  • 12:50pm
    Closing remarks from the Chair

FT Coverage 2014 Event

Pharma: A blueprint for health? by Andrew Ward, Pharmaceuticals Correspondent, The Financial Times

Digital future signals more active role for the patient, by Andrew Ward, Pharmaceuticals Correspondent, The Financial Times

fallback

Venue

For discounted rate (£311 per room) please quote the event name when booking.
MARRIOTT HOTEL
Grosvenor Square
London W1K 6JP
Tel: +44 (0) 20 7499 6363

fallback

Accommodation

Attendees of the event can benefit from a discounted rate of £311.00 per room per night (inc VAT, excl Breakfast) at the Marriott Hotel. 

Book your group rate for FT Live

Alternatively call our reservations team on: 0800 221 222 and Quote: B2GA as a special group code.

Check-in Time from 4pm onwards and Check-Out Time is by 12 noon.

Please advise that any individuals who do not arrive or cancel their reservation at least 72 hours prior to the arrival will be charged one nights room rate as a cancellation fee.

fallback

Contact us

Funmbi Adenubi
Ticket And General Enquiries
Financial Times
Gigs Thoukidides
Sponsorship Opportunities
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Lara Cornaro
Marketing and Communication Enquiries
Financial Times

Lead Sponsor (1)

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 29,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Associate Sponsor (2)

Lloyds Bank Commercial Banking provides comprehensive expert financial services to businesses of all sizes, from small businesses, through to mid-sized businesses and multinational corporations.

These clients range from privately-owned firms to FTSE 100 PLCs, multinational corporations and financial institutions. 

Maintaining a network of relationship teams across the UK, as well as internationally, Lloyds Bank Commercial Banking delivers the mix of local understanding and global expertise necessary to provide long-term support to its clients.

Lloyds Bank Commercial Banking offers a broad range of finance beyond just term lending and this spans debt capital market funding, trade finance, securitisation facilities and working capital management solutions.  Its product specialists provide bespoke financial solutions including cash management, international trade, treasury and risk management services.’

Stephenson Harwood is a law firm of over 130 partners and 700 staff worldwide. Our people are committed to achieving the goals of our clients - listed and private companies, institutions and individuals.

We assemble teams of bright thinkers to match our clients' needs and give the right advice from the right person at the right time. Dedicating the highest calibre of legal talent to overcome the most complex issues, we deliver pragmatic, expert advice that is set squarely in the real world.

Our headquarters are in London, with nine offices across Asia, Europe and the Middle East. In addition we have forged close ties with other high quality law firms. This diverse mix of expertise and culture results in a combination of deep local insight and the capability to provide a seamless international service.

Supporting Partners (11)

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization.Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to:

Pharmafocus is a monthly newspaper for the UK and European pharmaceutical and biotech industry that provides high-quality news, analysis and industry intelligence.

Our dedicated team of journalists update the website, newspaper and e-newsletters daily with the latest international news and features. Pharmafocus covers a broad range of issues affecting the industry including all areas of the drug lifecycle, with a strong focus on drug development, clinical trials, sales and marketing, and market access. Launched in 1998 and requested by a readership of 14,000 senior industry professionals, Pharmafocus is the most-read and respected pharma news source in the marketplace.

Founded 25 years ago at the infancy of biotechnology, the UK BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience.  Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.

The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media.  Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.

Bionow is the life-sciences membership organisation for the North of England and supports business growth, competitiveness and innovation within the biomedical and life science sectors. Bionow’s membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses. 

BioPartner UK is the independent, accredited trade organisation that promotes international partnering for trade, investment and collaborations with UK life science enterprises. BioPartner’s UK Delegations promote the UK presence at international conferences. We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to government grants and entry fee discounts for all UK-based organisations. 

EuropaBio, the European Association for Bioindustries, is the leading biotech trade association promoting an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. In healthcare, EuropaBio members include companies using biotech to develop or manufacture medicines, vaccines and diagnostic tools. The wider membership contains 77 corporate and associate members and biotech regions, and 16 national biotech associations in turn representing over 1800 biotech SMEs.

Read more about our work at www.europabio.org and our thought leadership and latest achievements in the State of European Biotech Address.

The European Medical Journal is an independent, open-access eJournal dedicated to delivering first-class insights into ground-breaking changes, and advancements in medicine. Spanning sixteen therapeutic areas, including Innovations, Cardiology, Oncology, and more, each journal provides the reader with the latest medical congress highlights, abstract reviews, and peer-reviewed articles to name but a few of its wide content selection. Flagship EMJ journals are also published quarterly, bringing an assortment of research papers from a variety of topics.

European Pharmaceutical Review is the leading bi-monthly publication for information on technologies in drug discovery and manufacturing. Every issue offers a high level of technical and business contributions from the world's leading pharmaceutical companies and academic institutions, coupled with new and exciting features including interviews, updates and profiles. 

MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales. MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine, LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe’s largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers. 

PharmaBoardroom.com’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 

China

Switzerland

France 

UK